Cargando…
Current Advances in the Treatment of BRAF-Mutant Melanoma
Melanoma is the most lethal form of skin cancer. Melanoma is usually curable with surgery if detected early, however, treatment options for patients with metastatic melanoma are limited and the five-year survival rate for metastatic melanoma had been 15–20% before the advent of immunotherapy. Treatm...
Autores principales: | Patel, Hima, Yacoub, Nour, Mishra, Rosalin, White, Aaron, Yuan, Long, Alanazi, Samar, Garrett, Joan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072236/ https://www.ncbi.nlm.nih.gov/pubmed/32092958 http://dx.doi.org/10.3390/cancers12020482 |
Ejemplares similares
-
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021) -
BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels
por: Yuan, Long, et al.
Publicado: (2020) -
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023) -
HER3 signaling and targeted therapy in cancer
por: Mishra, Rosalin, et al.
Publicado: (2018) -
Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma
por: Yuan, Long, et al.
Publicado: (2018)